Pharmacokinetics of nevirapine in human immunodeficiency virus type 1 infected pregnant women and their neonates

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 368-374

  Mirochnick, Mark ^a   Fenton, Terry ^b   Gagnier, Paul ^b   Pav, Joseph ^b   Gwynne, Meg ^b   Siminski, Sue ^b   Sperling, Rhoda S ^b   Beckerman, Karen ^b   Jimenez, Eleanor ^b   Yogev, Ram ^b   Spector, Stephen A ^b   Sullivan, John L ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PLACENTAL TRANSFER; PREGNANCY; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 17344368990     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515641     Document Type: Article

References (15)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Centers for Disease Control and Prevention. Recommendations for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43(RR-11):1-20.
3. Report of a consensus workshop. Maternal factors involved in mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 1992;5:1019-29.
4. Merluzzi VJ, Hargrave KD, Grozinger K, et al. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 1990;250:1411-3.
5. Havlir D, Cheeseman SH, McLaughlin M, et al. High dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:534-45.
6. Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. J Virol 1996;70:628-34.
7. Grob PM, Cao Y, Muchmore E, et al. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nature Med 1997;3:665-70.
8. Bauer LA, Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci 1983;72:978-9.
9. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1995;8:141-51.
10. Lamson MJ, Cort S, Sabo JP, MacGregor TR, Keirns JJ. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine 200 mg/day [abstract]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: International Conference on AIDS Society, 1996.
11. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993;37:178-82.
12. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1 - infected children. J Infect Dis 1996;174:713-21.
13. Norris SH, Silverstein HH, St George RL, Johnstone JN. Nevirapine, an HIV-1 reverse transcriptase inhibitor: absorption, distribution, and excretion in rats. Pharmacol Res 1992;9:5263.
14. Murphy RL, Montaner JL. Nevirapine: a review of its development, pharmacological profile, and potential for clinical use. Expert Opin Invest Drugs 1996;5:1183-99.
15. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin North Am 1997;44:55-77.